Progyny, Inc.

PGNY

US74340E1038

Managed Healthcare

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
32.4 ^USD	-2.00%		-1.07%	-12.86%

Mar. 12	Transcript : Progyny, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM
Mar. 05	Progyny Insider Sold Shares Worth $403,260, According to a Recent SEC Filing	MT

Progyny, Inc.(NasdaqGS:PGNY) added to S&P 400 Health Care

April 20, 2021 at 12:00 am EDT

Progyny, Inc.(NasdaqGS:PGNY) added to S&P 400 Health Care (Sector)

Latest news about Progyny, Inc.

Transcript : Progyny, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM	Mar. 12
Progyny Insider Sold Shares Worth $403,260, According to a Recent SEC Filing	Mar. 05	MT
Progyny Announces $100 Million Share Repurchase Program; Shares Rise	Feb. 29	MT
Progyny, Inc. announces an Equity Buyback for $100 million worth of its shares.	Feb. 29	CI
Progyny, Inc. authorizes a Buyback Plan.	Feb. 28	CI
Progyny Shares Slump After Q4 Results	Feb. 28	MT
KeyBanc Adjusts Price Target on Progyny to $43 From $45, Maintains Overweight Rating	Feb. 28	MT
North American Morning Briefing : Stock Futures Fall Ahead of Key Inflation Data	Feb. 28	DJ
Progyny Q4 Adjusted Earnings, Revenue Rise	Feb. 28	MT
Transcript : Progyny, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Progyny, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Period Ending December 31, 2024	Feb. 27	CI
Earnings Flash (PGNY) PROGYNY Reports Q4 EPS $0.32, vs. Street Est of $0.12	Feb. 27	MT
Earnings Flash (PGNY) PROGYNY Reports Q4 Revenue $269.9M, vs. Street Est of $274.1M	Feb. 27	MT
(PGNY) PROGYNY Forecasts Fiscal Year 2024 EPS $1.54 - $1.59	Feb. 27	MT
Progyny, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Progyny Insider Sold Shares Worth $769,928, According to a Recent SEC Filing	Feb. 08	MT
Progyny Chosen as Preferred Fertility Benefits Provider by Vistia Health	Jan. 17	MT
Vistia Health Selects Progyny, Inc. as Its Preferred Fertility and Family Building Benefits Provider	Jan. 17	CI
Progyny Names Chief Commercial Officer, Chief Technology Officer	Jan. 11	MT
Progyny Insider Sold Shares Worth $2,500,156, According to a Recent SEC Filing	Jan. 11	MT
Progyny, Inc. Announces Executive Appointments	Jan. 11	CI
Transcript : Progyny, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 08:15 AM	Jan. 09
Progyny Insider Sold Shares Worth $605,106, According to a Recent SEC Filing	Jan. 05	MT
Progyny Insider Sold Shares Worth $914,745, According to a Recent SEC Filing	Jan. 05	MT
Progyny Insider Sold Shares Worth $5,898,285, According to a Recent SEC Filing	Dec. 29	MT

Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Companyâs clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a memberâs full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.

Sector

Managed Healthcare

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Progyny, Inc. : Want to have a baby?

October 16, 2023 at 01:55 pm EDT

More Strategies

Ratings for Progyny, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

33.06 USD

Average target price

46.9 USD

Spread / Average Target

+41.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Managed Healthcare

	1st Jan change	Capi.
PROGYNY, INC.	-12.86%	3.18B
ELEVANCE HEALTH, INC.	+13.01%	124B
CIGNA	+17.77%	100B
CENTENE CORPORATION	+2.18%	40.43B
HUMANA INC.	-28.36%	39.21B
MOLINA HEALTHCARE, INC.	+0.53%	21.2B
ALIGNMENT HEALTHCARE, INC.	-39.84%	947M
CLOVER HEALTH INVESTMENTS, CORP.	-33.84%	308M

Other Managed Healthcare

Progyny, Inc.

Equities

PGNY

US74340E1038

Managed Healthcare

Progyny, Inc.(NasdaqGS:PGNY) added to S&P 400 Health Care

Latest news about Progyny, Inc.

Chart Progyny, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Progyny, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Managed Healthcare